| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand Name | Erbitux | |
| 3 | Generic Name | cetuximab | |
| 4 | Economics | ImClone | |
| 5 | Clinical Trials | ||
| 6 | Phase III FLEX study - 1L NSCLC - Presented ASCO 2008 | ||
| 7 | 1.2 month benefit shown. 1.4 months seen in Caucasians. Adenocarcinoma saw 1.8 month benefit. | ||
| 8 | Cisplatin+Vinorelbine+-Erbitux in 1L mNSCLC | ||
| 9 | |||
| 10 | Phase III BMS099 - NSCLC - ASCO 2008? | ||
| 11 | Failed PFS but OS data forthcoming. | ||
| 12 | |||
| 13 | Phase III CRYSTAL mCRC - Full survival data in 2H08 | ||
| 14 | 8.9 month PFS vs 8.0 month for placebo p<0.05. HR=0.85. | ||
| 15 | Large benefit seen in KRAS wild-type (non-mutant) patients. |